MARKET

LPCN

LPCN

Lipocine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.070
0.000
0.00%
After Hours: 2.070 0 0.00% 19:34 08/13 EDT
OPEN
2.120
PREV CLOSE
2.070
HIGH
2.140
LOW
2.030
VOLUME
3.65M
TURNOVER
--
52 WEEK HIGH
3.450
52 WEEK LOW
0.3010
MARKET CAP
135.76M
P/E (TTM)
-4.1575
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LPCN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

LPCN News

More
Lipocine EPS misses by $0.06
Lipocine (NASDAQ:LPCN): Q2 GAAP EPS of -$0.13 misses by $0.06. Unrestricted cash, cash equivalents and marketable investment securities of $18.3M. Press Re
seekingalpha · 08/06 18:08
MPC, GERN among premarket gainers
Seeking Alpha - Article · 08/03 12:27
Lipocine shares are trading higher after the company announced the publication of its LPCN 1144 liver fat study results in a peer-reviewed journal.
Benzinga · 08/03 12:15
Lipocine Announces Publication of LPCN 1144 Liver Fat Study Results in a Peer Reviewed Journal
Benzinga · 08/03 12:04
Lipocine regains compliance with Nasdaq listing rule
Lipocine (NASDAQ:LPCN) has regained compliance with Nasdaq minimum bid price requirement of $1.00 for continued listing. Shares +2% premarket. Previously:
seekingalpha · 07/13 17:09
Lipocine shares are trading higher after the company announced it regained compliance with the Nasdaq minimum bid price requirement. UPDATE: Shares have since reversed, now lower.
Benzinga · 07/13 13:56
Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement
Benzinga · 07/13 12:21
CLNE, NTES among premarket gainers
Seeking Alpha - Article · 07/09 12:19

Industry

Biotechnology & Medical Research
+1.09%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About LPCN

Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products. The Company's primary development programs are based on oral delivery solutions for bioavailable drugs. The Company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitates lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminates gastrointestinal interactions that limit bioavailability. Its lead product candidate, TLANDO, is an oral testosterone replacement therapy. Its additional pipeline includes, an oral androgen therapy for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, LPCN 1144; a once daily oral testosterone replacement therapy, TLANDO XR (LPCN 1111); an androgen therapy for the treatment of NASH cirrhosis, LPCN 1148, and an oral therapy for the prevention of preterm birth, LPCN 1107.
More

Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.